SCHEMBL3095423

SCHEMBL3095423

Nc1cccc(NC(=O)O)c1O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 1/20 0.52
HDAC3 O15379 10/20 0.47
HDAC1 Q13547 10/20 0.47
HDAC2 Q92769 10/20 0.47
MAPK1 P28482 1/20 0.47
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
KDM4E B2RXH2 2/20 0.45
CASP3 P42574 1/20 0.45
SENP8 Q96LD8 1/20 0.45
HSD17B10 Q99714 1/20 0.45
SENP7 Q9BQF6 1/20 0.45
SENP6 Q9GZR1 1/20 0.45
NCOR2 Q9Y618 4/20 0.42
HDAC4 P56524 5/20 0.41
HDAC7 Q8WUI4 5/20 0.41
HDAC10 Q969S8 5/20 0.41
HDAC11 Q96DB2 5/20 0.41
HDAC8 Q9BY41 5/20 0.41
HDAC6 Q9UBN7 5/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7455097 0.82 ALDH1A1 (0.50) MMP2HDAC3HDAC1HDAC2MAPK1
SCHEMBL653241 0.81 HDAC3 (0.68) HDAC3HDAC1HDAC2MAPK1NPC1
SCHEMBL11291980 0.80 NPC1 (0.57) HDAC3HDAC1HDAC2MAPK1NPC1
SCHEMBL11290401 0.78 CDC25B (0.58) HDAC3HDAC1HDAC2MAPK1NPC1
SCHEMBL20577985 0.78 MEN1 (0.49) HDAC3HDAC1HDAC2MAPK1NPC1
SCHEMBL17796923 0.78 HDAC3 (0.50) HDAC3HDAC1HDAC2MAPK1NPC1
SCHEMBL564707 0.76 MMP2 (0.45) MMP2HDAC3HDAC1HDAC2MAPK1
SCHEMBL14157620 0.76 LMNA (0.46) MAPK1NPC1RAB9AKDM4EALDH1A1
SCHEMBL6820139 0.75 CXCR2 (0.60) NPC1RAB9ACASP3SENP8SENP7
SCHEMBL10985405 0.74 MEN1 (0.50) HDAC3HDAC1HDAC2MAPK1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1661892-B1 CONDENSED RING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO (JP) 2013-07-24 EP disclosed
US-8318952-B2 Substituted indole derivatives for the treatment of respiratory diseases ONO PHARMACEUTICAL CO., LTD. (JP) 2012-11-27 US disclosed
EP-2481732-A1 Condensed ring compound and use thereof Ono Pharmaceutical Co., Ltd. (JP) 2012-08-01 EP disclosed
US-20100234368-A1 CONDENSED RING COMPOUND AND USE THEREOF TAKEUCHI JUN 2010-09-16 US disclosed
CN-101374818-A Pyrimidine derivatives ASTRAZENECA AB (SE) 2009-02-25 CN disclosed
EP-1661892-A1 CONDENSED RING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2006-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234368-A1 CONDENSED RING COMPOUND AND USE THEREOF CYSLTR2, CYSLTR1, LTB4R2 MMP2 3597/4885HDAC3 1524/4885HDAC1 1733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.